publication venue for
- NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma 2025
- Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper 2024
- Multiparameter flow cytometry in plasma cell disorders: when in doubt, go with the flow 2022
- High-risk transcriptional profiles in multiple myeloma are an acquired feature that can occur in any subtype and more frequently with each subsequent relapse 2021
- Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population 2020
- Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial 2019
- Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma 2015
- Retrospective observational study of patients with relapsed/refractory myeloma treated with pomalidomide - the UK Experience 2015
- MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome 2014